Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Identification of raloxifene as a novel CB2 inverse agonist.

Kumar P, Song ZH.

Biochem Biophys Res Commun. 2013 May 24;435(1):76-81. doi: 10.1016/j.bbrc.2013.04.040. Epub 2013 Apr 20.

2.

CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene.

Kumar P, Song ZH.

Biochem Biophys Res Commun. 2014 Jan 3;443(1):144-9. doi: 10.1016/j.bbrc.2013.11.071. Epub 2013 Nov 23.

3.

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.

Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG.

Br J Pharmacol. 1999 Feb;126(3):665-72.

4.

Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.

Mukherjee S, Adams M, Whiteaker K, Daza A, Kage K, Cassar S, Meyer M, Yao BB.

Eur J Pharmacol. 2004 Nov 28;505(1-3):1-9.

PMID:
15556131
5.

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.

Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT.

Neuropharmacology. 2005 Apr;48(5):658-72.

PMID:
15814101
6.

Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.

Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA, Sun SC, Resnick L, Chlenov M, He Y, Strassle BW, Cummons TA, Piesla MJ, Harrison JE, Whiteside GT, Kennedy JD.

Br J Pharmacol. 2007 Aug;151(7):1061-70. Epub 2007 Jun 4. Erratum in: Br J Pharmacol. 2007 Aug;151(7):1137.

7.

Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.

Zhang Y, Xie Z, Wang L, Schreiter B, Lazo JS, Gertsch J, Xie XQ.

Int Immunopharmacol. 2011 Sep;11(9):1303-10. doi: 10.1016/j.intimp.2011.04.013. Epub 2011 May 1.

8.

AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.

Bolognini D, Cascio MG, Parolaro D, Pertwee RG.

Br J Pharmacol. 2012 Apr;165(8):2561-74. doi: 10.1111/j.1476-5381.2011.01503.x.

9.

Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.

Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE.

Mol Pharmacol. 2006 Jul;70(1):41-50. Epub 2006 Mar 29.

10.

Cloning and pharmacological characterization of the dog cannabinoid CB₂receptor.

Ndong C, O'Donnell D, Ahmad S, Groblewski T.

Eur J Pharmacol. 2011 Nov 1;669(1-3):24-31. doi: 10.1016/j.ejphar.2011.08.002. Epub 2011 Aug 19.

PMID:
21871882
11.

In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.

Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T.

J Pharmacol Exp Ther. 2001 Feb;296(2):420-5.

12.

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG.

Br J Pharmacol. 2007 Mar;150(5):613-23. Epub 2007 Jan 22.

13.

Expression of functional CB1 cannabinoid receptors in retinoic acid-differentiated P19 embryonal carcinoma cells.

Svensson AC, Johansson M, Persson E, Carchenilla MS, Jacobsson SO.

J Neurosci Res. 2006 May 1;83(6):1128-40.

PMID:
16477621
15.

Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.

Ashton JC, Wright JL, McPartland JM, Tyndall JD.

Curr Med Chem. 2008;15(14):1428-43. Review.

PMID:
18537620
16.

Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine.

Ross RA, Brockie HC, Fernando SR, Saha B, Razdan RK, Pertwee RG.

Br J Pharmacol. 1998 Nov;125(6):1345-51.

17.
18.

Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.

Savinainen JR, Kokkola T, Salo OM, Poso A, Järvinen T, Laitinen JT.

Br J Pharmacol. 2005 Jul;145(5):636-45.

19.

Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.

Darmani NA, Janoyan JJ, Crim J, Ramirez J.

Eur J Pharmacol. 2007 Jun 1;563(1-3):187-96. Epub 2007 Feb 16.

20.

Involvement of β-arrestin-2 and clathrin in agonist-mediated internalization of the human cannabinoid CB2 receptor.

Chen X, Zheng C, Qian J, Sutton SW, Wang Z, Lv J, Liu C, Zhou N.

Curr Mol Pharmacol. 2014;7(1):67-80.

PMID:
25023974

Supplemental Content

Support Center